Eli Lilly and Co (LLY)
726.35
-19.60
(-2.63%)
USD |
NYSE |
Apr 19, 16:00
723.00
-3.35
(-0.46%)
After-Hours: 20:00
Eli Lilly Revenue (Quarterly): 9.353B for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 9.353B |
| September 30, 2023 | 9.499B |
| June 30, 2023 | 8.312B |
| March 31, 2023 | 6.96B |
| December 31, 2022 | 7.302B |
| September 30, 2022 | 6.942B |
| June 30, 2022 | 6.488B |
| March 31, 2022 | 7.81B |
| December 31, 2021 | 8.000B |
| September 30, 2021 | 6.773B |
| June 30, 2021 | 6.740B |
| March 31, 2021 | 6.806B |
| December 31, 2020 | 7.44B |
| September 30, 2020 | 5.741B |
| June 30, 2020 | 5.499B |
| March 31, 2020 | 5.860B |
| December 31, 2019 | 6.114B |
| September 30, 2019 | 5.477B |
| June 30, 2019 | 5.637B |
| March 31, 2019 | 5.092B |
| December 31, 2018 | 5.638B |
| September 30, 2018 | 5.307B |
| June 30, 2018 | 5.585B |
| March 31, 2018 | 4.964B |
| December 31, 2017 | 3.263B |
| Date | Value |
|---|---|
| September 30, 2017 | 5.658B |
| June 30, 2017 | 5.824B |
| March 31, 2017 | 5.228B |
| December 31, 2016 | 5.760B |
| September 30, 2016 | 5.192B |
| June 30, 2016 | 5.405B |
| March 31, 2016 | 4.865B |
| December 31, 2015 | 5.376B |
| September 30, 2015 | 4.960B |
| June 30, 2015 | 4.979B |
| March 31, 2015 | 4.645B |
| December 31, 2014 | 5.121B |
| September 30, 2014 | 4.876B |
| June 30, 2014 | 4.936B |
| March 31, 2014 | 4.683B |
| December 31, 2013 | 5.809B |
| September 30, 2013 | 5.773B |
| June 30, 2013 | 5.930B |
| March 31, 2013 | 5.602B |
| December 31, 2012 | 5.957B |
| September 30, 2012 | 5.443B |
| June 30, 2012 | 5.601B |
| March 31, 2012 | 5.602B |
| December 31, 2011 | 6.047B |
| September 30, 2011 | 6.148B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
5.477B
Minimum
Sep 2019
9.499B
Maximum
Sep 2023
6.987B
Average
6.806B
Median
Mar 2021
Revenue (Quarterly) Benchmarks
| Amgen Inc | 8.196B |
| Biogen Inc | 2.386B |
| Madrigal Pharmaceuticals Inc | -- |
| Vertex Pharmaceuticals Inc | 2.518B |
| Viking Therapeutics Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 2.190B |
| Total Expenses (Quarterly) | 5.813B |
| EPS Diluted (Quarterly) | 2.306 |
| Enterprise Value | 731.61B |
| Gross Profit Margin (Quarterly) | 80.88% |
| Profit Margin (Quarterly) | 23.41% |
| Earnings Yield | 0.78% |
| Operating Earnings Yield | 1.68% |
| Normalized Earnings Yield | 1.262 |